FACULTY/PRESENTER DISCLOSURE FACULTY: Arya Sharma, MD, PhD, FRCPC RELATIONSHIPS WITH COMMERICAL INTERESTS Boehringer-Ingelheim payment for development of educational presentations including service on speakers’ bureau Abbott Novo-Nordisk Allergan Johnson & Johnson Sanofi-Aventis

DISCLOSURE OF COMMERICAL SUPPORT Abbott National (Canada) Advisory Board for Sibutramine Merck International Advisory Board for anti-obesity drug Arena Echo-adjudication Committee for anti-obesity drug Vivus Consultancy for anti-obesity drug Novo-Nordisk National (Canada) Advisory Board for anti-diabetes drug Sanofi-Aventis National & International Advisory Boards for anti-obesity drug Glaxo-Smith-Kline (GSK) National Advisory Board for anti-obesity drug Boehinger-Ingelheim National & International Advisory Boards for anti-hypertensive and anti-diabetes Drug NeuroSearch International Advisory board for anti-obesity drug Allergan Consultant for surgical obesity device Glaxo-Smith-Kline Testimony for anti-obesity drug Obesity Treatment Survey

DISCLOSURE OF COMMERICAL SUPPORT Abbott payment for Consultancy/speakers’ bureau Merck payment for Consultancy Arena Vivus Novo-Nordisk Sanofi-Aventis Glaxo-Smith-Kline Boehringer-Ingelheim NeuroSearch Allergan Johnson & Johnson Payment for development of educational presentations including service on speakers’ bureau GRANTS FROM A COMMERICAL ORGANIZATION Abbott Obesity Treatment Survey

MITIGATING POTENTIAL BIAS There will not be any mention of off-label use of any commercial medications or treatments.